Co-located cell types help drive aggressive brain tumors, study finds
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...
Weakness in lung cancer's defenses found—an enzyme that boosts cancer cell metabolism
Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, ...
Healio22h
Over a quarter of stem cell transplant survivors develop cutaneous malignant neoplasms
More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.Researchers identified several risk factors, including older age, ...
Hosted on MSN3d
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo alone
A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...
The Lancet4d
Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study
Estimated geographical and temporal distribution of lung-cancer incidence varied across the four main subtypes worldwide. Our ...
CHMP recommends subcutaneous RYBREVANT® (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...
verywellhealth15d
Non-Small Cell Lung Cancer
Symptoms and treatment options depend on the stage of your lung cancer along with what type of NSCLC you're diagnosed with. There are three primary types: adenocarcinoma, squamous cell carcinoma, and ...
Pharmaceutical Technology18d
Volrustomig by AstraZeneca for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Squamous Non-Small Cell Lung ...
Pharmaceutical Technology18d
Izalontamab by Systimmune for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
SIB-001 is under development for the treatment of squamous non-small cell lung carcinoma, recurrent or metastatic head and neck squamous cell carcinoma, squamous non-small cell lung cancer, epithelium ...
Science Daily21d
Lung Cancer News
rare type of small cell lung cancer that primarily affects younger people who have never ... Aug. 23, 2024 — A team of researchers has created a digital pathology platform based on artificial ...
healthday24d
Diabetes Drug Protects Against Skin Cancer, New Research Says
People taking metformin had a lower risk of the two most common skin cancers However, Black patients were not protected against squamous cell cancer TUESDAY, Jan. 14, 2025 (HealthDay News) -- A ...